Polyethylene glycol recombinant human growth hormone in Chinese prepubertal slow-growing short children: doses reported in a multicenter real-world study

Jiajia Chen1†, Yan Zhong2†, Haiyan Wei3†, Shaoke Chen4, Zhe Su5, Lijun Liu6, Liyang Liang7, Ping Lu8, Linqi Chen9, Ruimin Chen10, Shining Ni11, Xinli Wang12, Li Li13, Yunfeng Wang14, Xu Xu15, Yanfeng Xiao16, Hui Yao17, Geli Liu18, Runming Jin19, Bingyan Cao1, Di Wu1, Chang Su1, Wenjing Li1, Miao Qin1, Xiaoqiao Li1, Xiaoping Luo20* and Chunxiu Gong1*

Abstract

Background: To evaluate the effectiveness of individualized-dose polyethylene glycol recombinant human growth hormone (PEG-rhGH) for short stature.

Methods: This real-world study enrolled children with short stature in 19 hospitals throughout China. They were treated with PEG-rhGH for 6 months. The starting dosage ranged from 0.10 to 0.20 mg/kg/week. The primary outcome was the change in height standard deviation score (ΔHt SDS).

Results: Five hundred and ten patients were included and grouped based on dosage as A (0.10–0.14 mg/kg/week), B (0.15–0.16 mg/kg/week), C (0.17–0.19 mg/kg/week), and D (0.20 mg/kg/week). The mean 6-month ΔHt SDS for the total cohort was 0.49 ± 0.27, and the means differed among the four dose groups (P = 0.002). The ΔHt SDS was lower in group A than in groups B (LSM difference [95%CI], -0.09 [-0.17, -0.01]), C (LSM difference [95%CI], -0.10 [-0.18, -0.02]), and D (LSM difference [95%CI], -0.13 [-0.21, -0.05]) after adjusting baseline covariates. There were no significant differences among groups B, C, and D. When the baseline IGF-1 was < -2 SDS or > 0 SDS, the ΔHt SDS was not different among the four groups (P = 0.931 and P = 0.400). In children with baseline IGF-1 SDS of -2 ~ 0 SDS, a higher dosage was associated with a better treatment effect (P = 0.003), and the ΔHt SDS was lower in older children than in younger ones (P < 0.001).

Conclusions: PEG-rhGH could effectively increase height in prepubertal short children. When the baseline IGF-1 was < -2 SDS, 0.10 mg/kg/week could be a starting dose. In other IGF-1 statuses, 0.15–0.20 mg/kg/week might be preferred.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Short stature is generally defined as height < -2 standard deviations for the population mean for age and sex or lower than the 3rd percentile of the growth curve of children of the same age and sex [1, 2]. It is the most common reason for referral to pediatric endocrinologists. Isolated short stature can be idiopathic or due to growth hormone deficiency (GHD). The diagnosis of GHD in childhood is complex. Idiopathic short stature (ISS) can be confused for GHD, and partial GHD is particularly difficult to distinguish from ISS [3–6].

Recombinant human growth hormone (rhGH) is the main treatment to normalize adult height and avoid extreme shortness in children and adolescents [2–4, 7]. Exogenous GH increases insulin-like growth factor (IGF-1), which promotes the growth of long bones [8]. rhGH was approved to treat short stature caused by many diseases, including GHD and ISS. The starting dose of rhGH and dose adjustments are mainly based on weight or body surface area and growth response. An individualized dosage of rhGH is required and aims for the lowest dose at which there is an appropriate response in height velocity. For patients with GHD, the treatment effect is often obtained even at a relatively low dosage of GH. For short stature caused by other diseases, the dose of rhGH is relatively large [9].

The currently used rhGH are mainly short-acting formulations, and a daily injection given at bedtime is required to mimic the normal daily profile of increased GH production at night [10, 11]. The long-term use of rhGH can lead to injection pain and poor compliance [12–14]. Polyethylene glycol recombinant human growth hormone (PEG-rhGH) is a long-acting formulation injected once per week [13–17]. The PEGylation of rhGH confers long-acting effects due to higher protein stability, reduced non-specific absorption and antigenicity, reduced renal clearance, and extended elimination half-life [15–17]. Pharmacokinetics curves showed that PEG-rhGH at 0.10–0.40 mg/kg persists in circulation for 192 h after injection [18]. Previous phase 1, 2, and 3 clinical trials demonstrated that compared with short-acting GH preparations, PEG-rhGH injection (Jintrolong®) at 0.20 mg/kg/week is effective and safe in treating children with GHD [18–20] and is probably not inferior to daily rhGH [19]. Hou et al. [20] reported a similar increase in IGF-1 between PEG-rhGH 0.20 mg/kg/week and rhGH 0.20 mg/kg/week.

PEG-rhGH was approved in January 2014 in China to treat GHD-related short stature in children. Long-acting GH formulations might improve compliance and consequently improve efficacy. Although PEG-rhGH has promising prospects in clinical practice, post-marketing data are lacking. In addition, the clinical trials only studied two dosages, limiting the generalizability of the findings, and there is an urgent need for real-world results [21, 22].

Therefore, this study aimed to evaluate the effectiveness of individualized-dose PEG-rhGH in children with short stature in a large-scale, prospective, real-world study. The results could reveal the influencing factors of the clinical effectiveness of PEG-rhGH for short stature children in China and examine the initial treatment dosage of PEGylated GH based on the IGF-1 levels at baseline.

Methods

Study design and participants

This multicenter real-world study enrolled children with short stature in 19 hospitals throughout China between January 2015 and December 2017. This study was approved by the Ethics Committees of the Beijing Children’s Hospital, Capital Medical University ([2015]-Y-001-C), and all other participating centers. The study was performed in accordance with the relevant guidelines and regulations. Written informed consents were obtained from all the children and their guardians. The participants were recruited according the criteria of the clinical trial (ClinicalTrials.gov: NCT03249480, 15/08/2017). However, partial participants did not strictly follow the original design of the clinical trial and were treated clinically. Then the physicians and the guardians decided the treatment together as in the real-world clinical practice.

The inclusion criteria were 1) met the diagnosis criteria of short stature, which included: i) absolute height lower than the 3rd percentile of the growth curve of the Chinese children population of the same age and sex, according to the height data reported by the 2005 national survey in China [23], ii) growth velocity (GV) of ≤ 5.0 cm/year, iii) peak plasma GH concentration < 10.0 ng/mL in two stimulation tests with different mechanisms within 1 year before starting treatment, and iv) bone age (BA) ≤ 9 years.
for girls, and ≤10 years for boys, 2) prepubertal status (Tanner stage I), 3) ≥3 years old, and 4) did not receive hGH treatment within the last 6 months.

The exclusion criteria were 1) liver and/or renal insufficiency with alanine transaminase (ALT) > twofold the upper limit of normal (ULN) or creatinine (Cr) > ULN, 2) positive hepatitis B virus examination including HBcAb, HBsAg, and HBeAg, 3) known highly allergic constitution or allergic to the study drug, 4) diabetes, 5) severe cardiopulmonary diseases, hematological diseases, malignant tumors, systemic infection, immune hypofunction, or psychiatric diseases, 6) other abnormalities in growth and development, including Turner syndrome, Laron syndrome, and GH receptor deficiency, 7) participation in other clinical trials of drugs within the last 3 months, or 8) congenital skeletal dysplasia.

**Treatment**
All children were treated with PEG-rhGH injection (Jintrolong®, GeneScience Pharmaceuticals, Changchun, China) once per week for 6 months. The individualized dosage was determined by the physicians based on clinical experience, ranging from 0.10 to 0.20 mg/kg/week. The dosages of PEG-rhGH were not adjusted during the treatment period.

**Data collection**
The clinical data, including sex, age, body temperature, heart rate, respiration, blood pressure, height, weight, and Tanner stage, were collected. The laboratory examination included blood routine test, liver and renal functions, electrolytes, blood lipid, thyroid functions, cortisol, adrenocorticotropic hormone (ACTH), GH stimulation test, insulin-like growth factors-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), anti-hGH antibody, and chromosome karyotypes (for female patients). The imaging examinations included X-ray for BA, anteroposterior and lateral X-ray of the whole spine, and pituitary magnetic resonance imaging (MRI). Electrocardiogram was also monitored.

The height and body weight of the children were measured by specially assigned investigators in each study center, using the specially assigned weighing machine and height-measuring device. The Atlas of Greulich and Pyle was used for the assessment of BA. IGF-1 and IGFBP-3 levels were measured by the chemiluminescence method (Immulette 2000 analyzer; Siemens, Erlangen, Germany). The children were carefully followed up and examined before, during, and after treatment, and the indicators of effectiveness and safety were monitored and recorded. No dietary restrictions were applied in this study, and the children were ensured with sufficient nutrition intake to maintain normal nutritional status. The children were required to avoid exercise for one day before screening and follow-up examinations.

**Follow-up and outcomes**
During the 26 weeks of intervention, the children were examined four times, i.e., at baseline and 4, 13, and 26 weeks of treatment.

The primary outcome was the height standard deviation score (Ht SDS) by the chronological age (CA) at the end of 26 weeks of treatment. \( \Delta \text{Ht SDS}_{CA} \) was defined as the Ht SDS at 26th week – height SDS at baseline. Height SDS = (height at the assessment – the average height of normal children of the same age and sex) / (standard deviation of height of normal children of the same age and sex).

The secondary outcome was the blood IGF-1 standard deviation score (IGF-1 SDS). Blood IGF-1 SDS = (actual IGF-1 level – median IGF-1 level of normal children of the same age and sex) / (the standard deviation of IGF-1 level of normal children of the same age and sex).

The safety indicators included tolerability indicators, thyroid function, liver, and renal functions, blood glucose, glucose metabolism indicators, blood lipid, anti-hGH antibody positive, and general manifestations. The tolerability indicators were injection reactions of the local skin, allergy, limb pain, joint pain, gynecomastia, benign intracranial hypertension, intermittent claudication, slipped capital femoral epiphysis, scoliosis, peripheral edema, etc.

**Statistical analysis**
The continuous data were tested for normal distribution using the Kolmogorov–Smirnov test. Continuous data with a normal distribution were described as mean ± standard deviations and tested using analysis of variance (ANOVA) and the least significant difference (LSD) post hoc test for intergroup comparison and paired t-test for intragroup comparison. Continuous data without normal distribution were described as median (IQR, interquartile range) and tested using the Kruskal–Wallis non-parametric test. Categorical data were described as n (%) and tested using the chi-square test or Fisher’s exact test. The significant \( P < 0.05 \) variables in the univariable analyses were included in a multivariable analysis. Furthermore, the covariance analysis model was applied to assess the 6-month \( \Delta \text{Ht SDS} \), with the dosage being the fixed effect and with the other baseline characteristics (such as IGF-1 SDS, sex, and baseline age) as covariates. The least-squares mean (LSM) estimates
of 6-month ΔHt SDS in each dosage group were calculated. The differences in LSM among the different dosage groups with 95% CI were shown. The statistical analyses were two-sided, and \(P\)-values < 0.05 were considered statistically significant.

**Results**

**Characteristics of the children**

A total of 699 children were screened, and 189 were excluded owing to incomplete data. Eventually, 510 children, including 330 boys (64.71%) and 180 girls (35.29%), were included from the 19 hospitals. The children were divided into groups A (0.10 mg/kg/week \(\leq\) PEG-rhGH < 0.15 mg/kg/week), B (0.15 mg/kg/week \(\leq\) PEG-rhGH < 0.17 mg/kg/week), C (0.17 mg/kg/week \(\leq\) PEG-rhGH < 0.20 mg/kg/week), and D (PEG-rhGH 0.20 mg/kg/week) according to the initial dosage. The baseline characteristics of the children are shown in Table 1. The children in group D were younger than those in groups A and C (\(P=0.033\) and \(P=0.016\), respectively), while there were no significant differences between groups B and D (\(P=0.103\)). The children in group D had lower baseline BA/CA than those in group C (LSM difference [95%CI], -0.04 [-0.07, -0.01], \(P<0.001\)), and higher BA/CA than those in group B (LSM difference [95%CI], 0.04 [-0.02, 0.07], \(P=0.002\)), while there were no significant differences between groups A and B (LSM difference [95%CI], 0.02 [-0.03, 0.06], \(P=0.432\)) and between groups A and D (LSM difference [95%CI], -0.03 [-0.07 ~ 0.01] \(P=0.192\)). According to MRI, 25 (4.9%) patients were suspected of having pituitary stalk occlusion syndrome. All others had a normal brain MRI. Among the 510 children, 171 (33.5%) had a GH peak < 5 µg/L (the median GH peak was 6.11 (4.35–7.72) µg/L). In addition, 35 (6.9%) were previously treated with GH. Table 1 shows the distribution of IGF-1 SDS and GH peaks per dose group.

**Effectiveness and multivariate analysis**

The 6-month ΔHt SDS for the total cohort was 0.49 ± 0.27, and the means were different among the four groups (\(P=0.002\)). The best therapeutic effect was observed in group D (0.54 ± 0.27), which was higher than in group A (0.38 ± 0.30) (\(P=0.0004\) and \(P=0.015\), respectively). The 6-month ΔHt SDS of groups B (0.48 ± 0.28) and C (0.46 ± 0.24) was numerically higher than in group A (Fig. 1).

The covariance analysis showed that dosage was associated with the 6-month ΔHt SDS (\(P=0.01\)) after adjusting for baseline covariates. The 6-month ΔHt SDS of group A was lower than in groups B (LSM difference [95%CI], -0.09 [-0.17, -0.01]), C (LSM difference [95%CI], -0.10

| Characteristics | Total (n = 510) | A (n = 47) | B (n = 129) | C (n = 121) | D (n = 213) | \(P\) value |
|-----------------|----------------|------------|------------|------------|------------|------------|
| Age, year, mean ± SD | 8.03 ± 2.67 | 8.57 ± 3.24 | 8.13 ± 2.63 | 8.38 ± 2.34 | 7.65 ± 2.69 | 0.036 |
| Sex, N (%) | | | | | | 0.191 |
| Male | 330 (64.71) | 34 (72.34) | 89 (68.99) | 80 (66.12) | 127 (59.62) | | |
| Female | 180 (35.29) | 13 (27.66) | 40 (31.01) | 41 (33.88) | 86 (40.38) | | |
| HT SDS, mean ± SD | -2.69 ± 0.80 | -2.77 ± 1.13 | -2.73 ± 0.72 | -2.60 ± 0.59 | -2.69 ± 0.87 | 0.530 |
| Weight SDS, mean ± SD | -1.39 ± 0.65 | -1.32 ± 0.87 | -1.34 ± 0.65 | -1.37 ± 0.58 | -1.44 ± 0.64 | 0.429 |
| BMI SDS, mean ± SD | -0.36 ± 1.09 | -0.24 ± 1.19 | -0.22 ± 1.11 | -0.47 ± 1.16 | -0.40 ± 1.03 | 0.245 |
| BA, mean ± SD | 5.75 ± 2.25 | 5.96 ± 2.58 | 5.55 ± 2.27 | 6.31 ± 1.96 | 5.50 ± 2.26 | 0.009 |
| BA/CA, median (IQR) | 0.720 (0.63–0.80) | 0.720 (0.60–0.79) | 0.680 (0.58–0.77) | 0.770 (0.69–0.82) | 0.720 (0.63–0.80) | < 0.0001 |
| IGF-1 SDS, median (IQR) | -0.93 (-1.42 ~ -0.43) | -0.88 (-1.38 ~ -0.37) | -1.00 (-1.48 ~ -0.43) | -0.99 (-1.38 ~ -0.65) | -0.87 (-1.39 ~ -0.35) | 0.801 |
| GH peak, µg/l, median (IQR) | 6.11 (4.35 ~ 7.72) | 5.70 (3.17 ~ 7.41) | 5.66 (3.74 ~ 7.40) | 6.86 (4.97 ~ 8.01) | 6.17 (4.54 ~ 7.76) | 0.004 |
| GH peak, N (%) | | | | | | 0.023 |
| < 5 µg/l | 171 (33.53) | 20 (42.55) | 56 (43.41) | 31 (25.62) | 64 (30.50) | | |
| 5-7 µg/l | 146 (28.63) | 14 (29.79) | 34 (26.36) | 33 (27.27) | 65 (30.52) | | |
| > 7 µg/l | 193 (37.84) | 13 (27.66) | 39 (30.23) | 57 (47.11) | 84 (40.44) | | |
| Pituitary gland MRI, N (%) | | | | | | 0.047 |
| Normal | 485 (95.10) | 42 (89.36) | 122 (94.57) | 120 (99.17) | 201 (94.37) | | |
| Suspected Pituitary stalk blocking syndrome | 25 (4.90) | 5 (10.64) | 7 (5.43) | 1 (0.83) | 12 (5.63) | | |
| Previously treated with GH, N (%) | 35 (6.86) | 3 (6.38) | 6 (4.65) | 5 (4.13) | 21 (9.86) | 0.145 |

*Baseline age = (date of signing informed consent – date of birth + 1)/365.25; the results are described with two decimals*

SD standard deviation, \(Ht\) height, SDS standard deviation score, BMI body mass index, BA bone age, IGF-1 insulin-like growth factor-1, GH growth hormone.
Chen et al. BMC Endocrine Disorders (2022) 22:201

The multivariable analysis showed that PEG-rhGH dosage ($\beta=2.173$, 95%CI: 1.250–3.095, $P<0.001$) was positively associated with the 6-month ΔHt SDS; baseline BA/CA ($\beta=-0.285$, 95%CI: -0.478, -0.092, $P=0.004$) and baseline IGF-1 SDS ($\beta=-0.031$, 95%CI: -0.060, -0.002, $P=0.038$) were negatively associated with the 6-month ΔHt SDS. Baseline Ht SDS ($P=0.768$), baseline BMI SDS ($P=0.066$), female ($P=0.828$), and GH peak ($P=-0.008$) were not associated with the 6-month ΔHt SDS (Table 3).

### Subgroup analysis
The interaction analysis between baseline IGF-1 SDS and dosage showed that the baseline IGF-1 interacts with dosage (Fig. 2 and Table S1). The 6-month ΔHt SDS was

![Fig. 1 The distribution of 6-month ΔHt SDS in different groups](image)

**Table 2** The covariance analysis of dosage group and 6-month ΔHt SDS

| Covariance                  | F-value | P-value  |
|----------------------------|---------|----------|
| Baseline IGF-1 SDS group   | 13.38   | <.0001   |
| Dosage group               | 3.85    | 0.0096   |
| Baseline age               | 24.64   | <.0001   |
| Baseline Ht SDS            | 1.69    | 0.1948   |
| Baseline BA                | 0.25    | 0.6142   |
| Baseline BMI SDS           | 3.64    | 0.0568   |
| Gender                     | 5.2     | 0.0230   |
| GH peak                    | 1.28    | 0.2586   |

The 6-month ΔHt SDS according to dosage:

- LSM (95% CI) in group A: 0.43 (0.36, 0.51)
- LSM (95% CI) in group B: 0.52 (0.46, 0.57)
- LSM (95% CI) in group C: 0.53 (0.47, 0.58)
- LSM (95% CI) in group D: 0.56 (0.52, 0.60)
- (A-B) LSM Difference (95%CI): -0.09 (-0.17, -0.01)
- (A-C) LSM Difference (95%CI): -0.10 (-0.18, -0.02)
- (A-D) LSM Difference (95%CI): -0.13 (-0.21, -0.05)
- (B-C) LSM Difference (95%CI): -0.01 (-0.07, 0.05)
- (B-D) LSM Difference (95%CI): -0.04 (-0.10, 0.01)
- (C-D) LSM Difference (95%CI): -0.03 (-0.09, 0.02)

**Table 3** The multivariate regression analysis of prognostic factors of 6-month ΔHt SDS

| Variable                  | $\beta$ (95% CI) | P       |
|---------------------------|------------------|---------|
| Baseline BA/ Baseline CA  | -0.285 (-0.478, -0.092) | 0.0039  |
| Baseline Ht SDS           | -0.0045 (-0.038, 0.028) | 0.7677  |
| Dosage                    | 2.173 (1.250, 3.095) | <0.0001 |
| Baseline IGF-1 SDS        | -0.031 (-0.060, -0.002) | 0.0378  |
| Baseline BMI SDS          | 0.0211 (-0.001, 0.043) | 0.0655  |
| Female                    | 0.005 (-0.044, 0.055) | 0.8281  |
| GH peak                   | -0.008 (-0.018, 0.002) | 0.1230  |

ΔHt height, SDS standard deviation score, CI confidence interval, BA bone age, CA chronological age, IGF-1 insulin growth factor-1, BMI body mass index, GH growth hormone.
not significantly different with different dosages among children with baseline IGF-1 < -2 SDS \((P = 0.931)\), suggesting that the height gain was not significantly associated with the PEG-rhGH dosage. When the baseline IGF-1 SDS was between -2 SDS and 0 SDS, differences among the dosage groups were observed \((P = 0.003)\). The dosages were linearly correlated with the treatment effectiveness, with higher dosages exerting higher height gains. When the baseline IGF-1 was > 0 SDS, the ΔHt SDS was not significantly different among the dosage groups \((P = 0.398)\) (Table S1).

In the patients with IGF-1 SDS between -2 SDS and 0 SDS, subgroup analysis by baseline age subgroups (<7, 7–9, and >9) showed that ΔHt SDS was negatively correlated with age. The correlation coefficient Rho was -0.5 \((P < 0.001)\), suggesting that the increase in Ht SDS was lower after 6 months of treatment in older children. In addition, the dosage was weakly correlated with age. The correlation coefficient Rho was -0.11 \((P = 0.022)\), suggesting that the treatment dosage was less changed in older children and that the dosage tended to decrease gradually.

Safety
The overall safety was good, and the treatment was tolerable. The incidence rates of treatment drug-related adverse responses (ADR) were 4/47 (8.51%), 11/129 (8.53%), 17/121 (14.05%), and 26/213 (12.21%) in groups A, B, C, and D, respectively. No severe adverse events (SAEs) were observed in group A. Two patients (2/129, 1.55%) in group B had SAEs, including head trauma and pneumonia. One patient (1/121, 0.83%) in group C had enteritis. No SAEs occurred in group D. Overall, two patients developed peripheral edema. No lipodystrophy was observed.

Discussion
This study aimed to evaluate the effectiveness of individualized-dose PEG-rhGH treatment in children with short stature in a multicenter, large-scale, prospective, real-world study. We tried to examine the dosage for the initial PEG-rhGH application. PEG-rhGH is effective with different dosages ranging from 0.10 mg/kg/week to 0.20 mg/kg/week for children with short stature. The baseline factors such as BA/CA, baseline IGF-1 SDS, and dosage affect the 6-month ΔHt SDS, while the baseline of Ht SDS and BMI SDS, sex, and the GH peak did not. The previous phase 3 trials showed the efficacy of PEG-rhGH over short-acting GH for the management of GHD. Indeed, the phase 3 trial by Luo et al. [19] was performed in 343 children and showed that the ΔHt
SDS was 0.90 ± 0.36 for the 0.10 mg/kg/week dosage and 1.01 ± 0.39 for the 0.20 mg/kg/week dosage, significantly different after 25 weeks. They also showed that children with peak GH levels ≤ 5 µg/L (severe GHD) had the largest changes in growth parameters compared with those with peak GH > 5 µg/L, but they analyzed the two dosages together. In a non-randomized study by Qiao et al. [9] et al., the Ht SDS increased from -2.57 ± 0.75 at baseline to -1.06 ± 0.85 at 24 months in children treated with PEG-rhGH. Other long-acting rhGH products showed similar results [12, 24, 25]. In the present study, the 6-month ΔHt SDS was 0.49 ± 0.27, which is a smaller improvement than previously reported. The 6-month ΔHt SDS increased with dosage, at 0.38 ± 0.30 for the 0.10–0.14 mg/kg/week dosage and 0.54 ± 0.27 mg/kg/week dosage, and with intermediate values for the 0.15–0.16 and 0.17–0.19 mg/kg/week dosages. This study was a real-world study of the treatment of prepubertal slow-growing children. The inclusion criteria for the short stature of children were not as strict as GHD patients in the phase 3 trial. The height increase at 6 months was smaller in the present study than in the phase 3 trials [12, 19, 25], which could be attributed to the stricter selection criteria in the phase 3 trials, while the present study included actual patients from routine clinical practices. The differences in patient selection led to differences such as lower GH peaks and lower median IGF-1 levels, which probably affected the growth outcomes. In addition, the starting dosage was not the same as in the phase 3 trials since it was based on the physicians’ clinical experience.

The hypothalamus-GH-IGF-1 axis is directly associated with growth [26], and IGF-1 is a commonly used marker of GH activity [25, 26]. The stratified analysis by baseline IGF-1 showed no dosage-dependent relationship between the 0.10 and 0.20 mg/kg/w dosages in the subgroups of baseline IGF-1 < -2 SDS and baseline IGF-1 > 0 SDS. It suggested that the height gain was not significantly associated with the PEG-rhGH dosage. Based on the baseline IGF-1 < -2 SDS, the clinical diagnosis is more likely to be GHD. The low initial dosage (0.10 mg/kg/week) could achieve a therapeutic effect. The number of patients with IGF-1 < -2 SDS was small, and studies with larger numbers are needed. Patients with baseline IGF-1 > 0 SDS were most likely not diagnosed with GHD in clinical practice. Although there were no statistically significant differences between the dose groups, the therapeutic effect of group A was numerically smaller than in the other groups. A dose of more than 0.20 mg/kg/week might be required to achieve a short-term therapeutic effect. Therefore, an initial dosage of 0.20 mg/kg/week might be recommended for patients with baseline IGF-1 > 0 SDS, while the subgroup of baseline IGF-1 of -2–0 SDS showed a significant association between treatment effectiveness and dosage. In addition, children with a younger age had better treatment effectiveness, suggesting that the treatment should be applied as early as possible. Ying et al. [8] showed that the factors affecting growth velocity were age at rhGH initiation, IGF-1 SDS during treatment and growth velocity in the year before treatment. Nevertheless, the subgroups in the present study were small and uneven in size. Future studies are necessary to confirm the results.

In addition, the children in group A were older than in the other groups. Due to the experience of clinicians or the results of the phase 2 trial, many clinicians believed that it is safer with a lower initial dosage. The age might be an important confounding factor in this study.

The present study did not report new safety signals compared with the previous phase 3 trial [19]. In the present study, no patient discontinued therapy due to ADRs. Still, SAEs did occur, including head trauma, pneumonia, enteritis, benign intracranial hypertension, upper respiratory infection, myocardial reperfusion injury, and tonsillitis. Of note, no SAEs were reported in the phase 3 trial [19], which might be because of patient selection. In the present study, no hypothyroidism [27], injection site lipoatrophy [27], or anti-rhGH antibodies [12, 25] were observed.

This study has some limitations. First, the follow-up is short, and long-term clinical outcomes are lacking. Second, dividing the patients into four dosage groups resulted in a small sample size of the 0.10–0.14 mg/kg/week group. Third, the sample size of the baseline IGF-1 < -2 SDS subgroup was small, and the results should be interpreted with caution. Further studies are needed to validate the findings in these children.

**Conclusions**

In conclusion, PEG-rhGH is effective for children with short stature, with dosages ranging from 0.10 mg/kg/week to 0.20 mg/kg/week. The baseline IGF-1 interacts with dosage: for children with baseline IGF-1 of < -2 SDS, 0.10 mg/kg/week as an initial dose could be effective; when the baseline IGF-1 was > -2 SDS, initiating at a higher dosage with 0.15–0.20 mg/kg/week might be the better.

**Abbreviations**

PEG-rhGH: Polyethylene glycol recombinant human growth hormone; Ht SDS: Height standard deviation score; ISS: Idiopathic short stature; GHD: Growth hormone deficiency; GH: Growth hormone; rhGH: Recombinant human growth hormone; GV: Growth velocity; BA: Bone age; ALT: Alanine transaminase; ULN: Upper limit of normal; Cr: Creatinine; ACTH: Adrenocorticotropic hormone; IGF-1: Insulin-like growth factors-1; IGFBP-3: Insulin-like growth factor binding protein-3; IGF-1: SDS IGF-1 standard deviation score; ANOVA: Analysis of variance; LSD: Least significant difference; ADR: Adverse responses.
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12902-022-01101-8.

Additional file 1: Table S1. The description of 6-month ΔHt SDS among children with different baseline characteristics and different treatment dosage.

Acknowledgements

The authors acknowledge the support of all the patients and their families included in the study.

Authors' contributions

Chunxiu Gong and Xiaoping Luo planned and designed the study. Jiajia Chen and Chunxiu Gong drafted the manuscript. Jiajia Chen performed statistical analysis with input from Yan Zhong, Haiyan Wei, Shaoke Chen, Zhe Su, Lijun Liu, Liyang Liang, Ping Lu, Linqi Chen, Ruimin Chen, Shining Ni, Xilin Wang, Li Li, Yunfeng Wang, Xu Xu, Yanfeng Xiao, Hui Yao, Gelli Liu, Running Jin, Bingyan Cao, Di Wu, Chang Su, Wenjing Li, Miao Qin1, Xioaqiao Li, Xiaoping Luo, Yan Zhong and Haiyan Wei critically revised the manuscript. Jiajia Chen, Yan Zhong, Haiyan Wei, Shaoke Chen, Zhe Su, Lijun Liu, Liyang Liang, Ping Lu, Linqi Chen, Ruimin Chen, Shining Ni, Xilin Wang, Li Li, Yunfeng Wang, Xu Xu, Yanfeng Xiao, Hui Yao, Gelli Liu, Running Jin, Bingyan Cao, Di Wu, Chang Su, Wenjing Li, Miao Qin1, Xioaqiao Li collected data. All authors(s) read and approved the final manuscript. Jiajia Chen and Chunxiu Gong read and approved the final manuscript.

Funding

This study was funded by the National Science and Technology Major Project (2017ZX09304029-001–002).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committees of the Beijing Children's Hospital, Capital Medical University (2015-Y-001-C) and all other participating centers. The study was performed in accordance with the relevant guidelines and regulations. Written informed consents were obtained from all the children or their guardians.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Endocrine and Genetics and Metabolism, Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health, No.56 Nanliuli Road, Xicheng District, 100045 Beijing, China. 2Department of Child Health Care, Huanan Children's Hospital, Changsha 410007, China. 3Department of Endocrinology and Metabolism, Genetics, Henan Children's Hospital (Children's Hospital Affiliated to Zhengzhou University), Changsha 450018, China. 4Department of Genetics and Metabolism, The Second Affiliated Hospital of Guangxi Medical University, Nanning 530005, China. 5Department of Endocrinology, Shenzhen Children's Hospital, Shenzhen 518038, China. 6Department of Endocrinology, Children's Hospital of Soochow University, Suzhou 215025, China. 7Department of Endocrinology and Metabolism, Fuzhou Children's Hospital of Fujian Medical University, Fuzhou 350005, China. 8Department of Endocrinology, Children's Hospital of Nanjing Medical University, Nanjing 210008, China. 9Department of Pediatrics, Peking University Third Hospital, Beijing 100191, China. 10Department of Pediatrics, The First People's Hospital of Yunnan Province, Kunming 650032, China. 11Department of Pediatrics, China-Japan Friendship Hospital, Beijing 100029, China. 12Department of Endocrinology, Wuxi Children's Hospital, Wuxi 214023, China. 13Department of Pediatrics, The 2nd Affiliated Hospital of Medical College of Xian Jiaotong University, Xian 710004, China. 14Department of Endocrinology and Metabolism, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430015, China. 15Department of Pediatrics, Tianjin Medical University General Hospital, Tianjin 300052, China. 16Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

Received: 22 July 2021Accepted: 12 July 2022

Published online: 09 August 2022

References

1. Barstow C, Rerucha C. Evaluation of Short and Tall Stature in Children. Am Fam Physician. 2015;92(1):43–50.
2. Regol AD, Hayden GF. Etiology and early diagnosis of short stature and growth failure in children and adolescents. J Pediatr. 2014;164(5 Suppl):S1-14.e16.
3. Alatzoglou KS, Webb EA, Le Tissier P, Dattani MT. Isolated growth hormone deficiency (IGHD) in childhood and adolescence: recent advances. Endocr Rev. 2014;35(3):376–432.
4. Stanley T. Diagnosis of growth hormone deficiency in childhood. Curr Opin Endocrinol Diabetes Obes. 2012;19(1):47–52.
5. Wit JM. ICPEd. International Classification of Pediatric Endocrine Diagnoses: Short stature. http://www.icped.org/revisions/0/2015/diagnoses/#/1. Accessed May 25, 2021; 2007.
6. Halas JG, Grimbarg A. Dilemmas of growth hormone treatment for GH deficiency and idiopathic short stature: defining, distinguishing, and deciding. Minerva Pediatr. 2020;72(3):206–25.
7. Grimbarg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, Rossi WC, Feudtner C, Murad MH, Drug, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr. 2016;86(6):361–97.
8. Ying YQ, Hou L, Liang Y, Wu W, Luo XP. Efficacy and safety of recombinant human growth hormone in treating Chinese children with idiopathic short stature. Growth Horm IGF Res. 2018;42:43–80–5.
9. Qiao Y, Wang Z, Han J, Li G. Use of Pegylated Recombinant Human Growth Hormone in Chinese Children with Growth Hormone Deficiency: A 24-Month Follow-Up Study. Int J Endocrinol. 2019;2019:1438723.
10. Sas TC, de Ridder MA, Wit JM, Rotteveel J, Gostijk W, Reeser HM, Otten BJ, de Muinck Keizer-Schrama SM. Adult height in children with growth hormone deficiency: a randomized, controlled, growth hormone dose-response trial. Horm Res Paediatr. 2010;74(3):172–81.
11. Coelho R, Brook CG, Preece MA, Stanhope RG, Dattani MT, Hindmarsh PC. A randomised study of two doses of biosynthetic human growth hormone on final height of pubertal children with growth hormone deficiency. Horm Res. 2008;70(2):85–8.
12. Khadilkar V, Radjuk KA, Bolshova E, Khadgawat R, El Kholy M, Desai M, Peterkova V, Mericq V, Kratzsch J, Siepl EC, et al. 24-month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency. J Clin Endocrinol Metab. 2014;99(1):126–32.
13. Yuan KC, Miller BS, Boguszewski CL, Hoffman AR. Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs. Front Endocrinol (Lausanne). 2021;12.
14. Miller BS, Velazquez E, Yuan KCJ. Long-Acting Growth Hormone Preparations - Current Status and Future Considerations. J Clin Endocrinol Metab. 2020;105(6):e2121–33. https://doi.org/10.1210/clinem/dgza149.
15. Rasmussen MH, Bystedt BV, Anderson TW, Kgitgaard T, Madsen J. Peglated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmaco kinetic...
and pharmacodynamic treatment profile. J Clin Endocrinol Metab. 2010;95(7):3411–7.

16. Webster R, Xie R, Didier E, Finn R, Finnessy J, Edgington A, Walker D. PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans. Xenobiotica. 2008;38(10):1340–51.

17. Søndergaard E, Kloese M, Hansen M, Hansen BS, Andersen M, Feldt-Rasmussen U, Laursen T, Rasmussen MH, Christiansen JS. Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency. J Clin Endocrinol Metab. 2011;96(3):681–8.

18. Guan Y, He E, Wu J, Zhao L, Wang X, Huang L, Zeng G, Ren B, Chen J, Liao X, et al. A long-acting pegylated recombinant human growth hormone (Jintrolong(R)) in healthy adult subjects: Two single-dose trials evaluating safety, tolerability and pharmacokinetics. J Clin Pharm Ther. 2018;43(5):640–6.

19. Luo X, Hou L, Liai L, Dong G, Shen S, Zhao Z, Gong CX, Li Y, Du ML, Su Z, et al. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies. Eur J Endocrinol. 2017;177(2):195–205.

20. Hou L, Chen ZH, Liu D, Cheng YG, Luo XP. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children. Drug Des Devel Ther. 2016;10:10–21.

21. Kim HS, Lee S, Kim JH. Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records. J Korean Med Sci. 2018;33(34):e213.

22. Zarbin M. Real life outcomes vs. clinical trial results. J Ophthalmic Vis Res. 2019;1(1):88–92.

23. Li H, Ji CY, Zong XN, Zhang YQ. Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years. Chinese journal of pediatrics. 2009;47(7):487–92.

24. Silverman BL, Blethen SL, Reiter EO, Attie KM, Neuwirth RB, Ford KM. A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency. J Pediatr Endocrinol Metab. 2002;15(Suppl 2):715–22.

25. Peter F, Bidlingmaier M, Savoy C, JI HJ, Saenger PH. Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD). J Clin Endocrinol Metab. 2012;97(2):400–7.

26. Blum WF, Alherbish A, Alshagheir A, El Awwa A, Kaplan W, Koledova E, Savage MO. The growth hormone-insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders. Endocr Connect. 2018;7(6):R212–22.

27. Allen DB, Backeljauw P, Bidlingmaier M, Biller BM, Boguszewski M, Burman P, Butler G, Chihara K, Christiansen J, Cianfarani S, et al. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol. 2016;174(2):P1-9.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.